Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine plus propofol versus fentanyl plus propofol for anesthesia during ERCP
ChiCTR1800016018Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nalbuphine, propofol, fentanyl and midazolam in None (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Hypoxemia, Upper airway obstruction and 2 more. Started May 2018; status: recruiting.
02
Drugs
nalbuphinepropofolfentanylmidazolam
Beyond the preview
Go deeper on ChiCTR1800016018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016018.